[{"id":"d5b7efa8-e965-442b-8575-71001ab87e87","acronym":"IGNYTE-ESO","url":"https://clinicaltrials.gov/study/NCT03967223","created_at":"2021-01-19T18:07:33.215Z","updated_at":"2024-07-02T16:35:07.685Z","phase":"Phase 2","brief_title":"Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors","source_id_and_acronym":"NCT03967223 - IGNYTE-ESO","lead_sponsor":"Adaptimmune","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 08/28/2024","primary_completion_date":" 08/28/2024","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-04-25"},{"id":"cf75cef8-fbca-4f5e-981f-7832552ff034","acronym":"","url":"https://clinicaltrials.gov/study/NCT05993299","created_at":"2023-08-15T19:10:23.528Z","updated_at":"2024-07-02T16:35:33.510Z","phase":"Phase 2","brief_title":"Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma","source_id_and_acronym":"NCT05993299","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • HLA-A*02 • CTAG1B expression • HLA-A2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 12/31/2019","start_date":" 12/31/2019","primary_txt":" Primary completion: 10/12/2022","primary_completion_date":" 10/12/2022","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2023-10-16"},{"id":"bdb8eace-af07-466b-a0e7-cc3562eb74f5","acronym":"ADP-0011-007","url":"https://clinicaltrials.gov/study/NCT02992743","created_at":"2021-02-16T02:53:04.030Z","updated_at":"2024-07-02T16:35:50.904Z","phase":"Phase 2","brief_title":"Letetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell Liposarcoma","source_id_and_acronym":"NCT02992743 - ADP-0011-007","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 23","initiation":"Initiation: 12/06/2016","start_date":" 12/06/2016","primary_txt":" Primary completion: 11/01/2021","primary_completion_date":" 11/01/2021","study_txt":" Completion: 03/22/2022","study_completion_date":" 03/22/2022","last_update_posted":"2023-04-11"},{"id":"8ea82e4e-0bda-4bce-8a02-900c33e4f243","acronym":"","url":"https://clinicaltrials.gov/study/NCT02588612","created_at":"2021-01-18T12:33:38.648Z","updated_at":"2024-07-02T16:36:24.831Z","phase":"Phase 1","brief_title":"Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT02588612","lead_sponsor":"GlaxoSmithKline","biomarkers":" EGFR • ALK • ROS1 • HLA-A • CTAG2","pipe":" | ","alterations":" EGFR mutation • ALK rearrangement • HLA-A*02 • CTAG2 expression","tags":["EGFR • ALK • ROS1 • HLA-A • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK rearrangement • HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 02/01/2016","start_date":" 02/01/2016","primary_txt":" Primary completion: 08/10/2020","primary_completion_date":" 08/10/2020","study_txt":" Completion: 08/10/2020","study_completion_date":" 08/10/2020","last_update_posted":"2021-09-05"},{"id":"371e00b7-13f0-4e7a-9ae5-dfcb18a5df87","acronym":"ADP 04511","url":"https://clinicaltrials.gov/study/NCT01343043","created_at":"2021-02-16T02:52:18.139Z","updated_at":"2024-07-02T16:36:28.459Z","phase":"Phase 1","brief_title":"A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma","source_id_and_acronym":"NCT01343043 - ADP 04511","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B","pipe":" | ","alterations":" HLA-A*02 • CTAG1B expression","tags":["HLA-A • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 09/27/2012","start_date":" 09/27/2012","primary_txt":" Primary completion: 06/18/2019","primary_completion_date":" 06/18/2019","study_txt":" Completion: 06/18/2019","study_completion_date":" 06/18/2019","last_update_posted":"2021-06-30"},{"id":"837e1307-aff9-47a1-8cb7-f58eedd670f4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03697824","created_at":"2021-01-18T18:07:24.635Z","updated_at":"2025-02-25T16:08:27.486Z","phase":"Phase 1b/2a","brief_title":"Clinical Trial of Safety, Tolerability and Antitumor Activity of Genetically Engineered T Cells in Combination With Anti-Cancer Agents in Relapsed and Refractory Synovial Sarcoma Expressing New York Esophageal Antigen-1 (NY-ESO-1) and/or LAGE-1a","source_id_and_acronym":"NCT03697824","lead_sponsor":"GlaxoSmithKline","biomarkers":" HLA-A • CTAG1B • CTAG2","pipe":" | ","alterations":" HLA-A*02 • CTAG2 expression","tags":["HLA-A • CTAG1B • CTAG2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • CTAG2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • letetresgene autoleucel (GSK3377794)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 02/25/2019","start_date":" 02/25/2019","primary_txt":" Primary completion: 07/18/2022","primary_completion_date":" 07/18/2022","study_txt":" Completion: 07/18/2022","study_completion_date":" 07/18/2022","last_update_posted":"2019-10-29"},{"id":"2b0121ff-99c4-4030-9c8c-850dfc76191c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01567891","created_at":"2021-02-16T02:52:20.305Z","updated_at":"2024-07-02T16:36:58.558Z","phase":"Phase 1/2","brief_title":"CT Antigen TCR-redirected T Cells for Ovarian Cancer.","source_id_and_acronym":"NCT01567891","lead_sponsor":"Adaptimmune","biomarkers":" CTAG1B","pipe":" | ","alterations":" CTAG1B expression","tags":["CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CTAG1B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letetresgene autoleucel (GSK3377794)"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 07/09/2013","start_date":" 07/09/2013","primary_txt":" Primary completion: 06/06/2017","primary_completion_date":" 06/06/2017","study_txt":" Completion: 06/06/2017","study_completion_date":" 06/06/2017","last_update_posted":"2019-06-27"}]